OptimizeRx (OPRX) Net Equity Issued and Repurchased (2014 - 2021)

OptimizeRx has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $70.7 million in Q1 2021.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $70.7 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $70.7 million (changed N/A YoY) and the FY2021 annual result came in at $70.7 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased advanced to $70.7 million in Q1 2021 per OPRX's latest filing, from $1.0 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $70.7 million in Q1 2021 and troughed at -$1.3 million in Q4 2018.
• A 4-year average of $11.7 million and a median of $328673.5 in 2018 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2019 and 2020: Net Equity Issued and Repurchased slumped 54.25% in 2019, then jumped 406.53% in 2020.
• Over 4 years, Net Equity Issued and Repurchased stood at -$1.3 million in 2018, then advanced by 17.45% to -$1.1 million in 2019, then jumped by 198.03% to $1.0 million in 2020, then surged by 6662.2% to $70.7 million in 2021.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $70.7 million, $1.0 million, and -$1.1 million for Q1 2021, Q3 2020, and Q4 2019 respectively.